Company intelligence / Profile preview

Heka

Chuo-ku, Tokyo, Japanheka.com ↗

Ownership: Private
Development stage: Commercial

Overview

HekaBio is a Japan-based healthcare investment and commercialization platform that accelerates patient access to innovative medicines and medical technologies across Asia-Pacific. It specializes in identifying early-stage, de-risked opportunities—primarily in CNS disorders, oncology, and healthy longevity—and brings them into Japan/APAC markets via licensing partnerships. The company synchronizes U.S./Japan development timelines for optimal commercial success. Recent strategic partnerships include Alfresa Holdings Corporation.

Therapeutic areas: OncologyNeurologyOther
Modalities: Small moleculeBiologicMedical deviceRegenerative medicine product
Industry: Investors

Partnerships

Alfresa Holdings Corporation (strategic partnership including capital investment)

Beyond the preview

Go deeper on Heka.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Heka.

Explore the full profile